Pharmaxis Ltd is an Australian biotechnology company focused on developing innovative therapies and diagnostic tests for respiratory and fibrotic diseases. Established in 1998 and headquartered in Sydney, the company has built a diversified portfolio spanning marketed products and a clinical-stage pipeline. Pharmaxis leverages expertise in small molecule chemistry and enzyme inhibition to address conditions with unmet medical needs.
Among its commercial offerings, Pharmaxis markets Aridol, a rapid inhalation test for airway hyperresponsiveness used by pulmonologists to aid in the diagnosis of asthma. Bronchitol, a dry powder mannitol therapy for cystic fibrosis, is approved for sale in Europe, Australia, and certain other territories, where it helps improve lung function and airway clearance. These products underscore the company’s ability to navigate regulatory pathways and bring novel respiratory solutions to market.
The company’s clinical pipeline features PXS-5505 and PXS-5338, small molecule inhibitors targeting lysyl oxidase enzymes implicated in progressive fibrotic diseases such as idiopathic pulmonary fibrosis and liver fibrosis. Pharmaxis conducts multi‐center clinical trials across North America, Europe, and Australia, collaborating with leading academic institutions and leveraging its in-house chemistry and toxicology capabilities to advance candidates from discovery through early development.
Under the leadership of Chief Executive Officer Gary Phillips, Pharmaxis emphasizes disciplined research and strategic partnerships. The executive team and board comprise seasoned professionals with backgrounds in pharmaceutical development, regulatory affairs, and commercial operations. With a focus on respiratory and fibrotic indications, Pharmaxis aims to expand its global footprint while continuing to innovate in niche therapeutic areas.
AI Generated. May Contain Errors.
